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Purpose: Factor I (FI) is a serine protease regulator of the complement system. Genetic
variants in CFI are associatedwith advanced age-relatedmacular degeneration (AAMD).
However, the clinical and functional impact of these variants is unknown. This study
assessed the functional significance of rare CFI variants using a serum-based assay.
Methods:Carriers of rare variantswith (n= 78) andwithout AAMD (n= 28), andnoncar-
riers with (n = 49) and without AMD (n = 44) were evaluated. Function of FI was deter-
mined bymeasuring the proteolytic cleavage of C3b to iC3b, using the cofactor protein,
Factor H.
Results: CFI variants were categorized into three groups based on antigenic and
functional assessments. Type 1 variants (n = 18) in 35 patients with AAMD demon-
strated low serum FI levels and a corresponding decrease in FI function. Type 2 variants
(n = 6) in 7 individuals demonstrated normal serum FI antigenic levels but reduced
degradation of C3b to iC3b. Type 3 variants (n = 15) in 64 individuals demonstrated
normal antigenic levels and degradation of C3b to iC3b. However, iC3b generation was
low when measured per unit of FI. Thus most rare CFI variants demonstrate either low
antigenic levels (type 1) or normal levels but reduced function (types 2 or 3).
Conclusions: Results provide for the first time a comprehensive functional assessment
in serumofCFI raregenetic variants and further establish FI’s key role in thepathogenesis
of AAMD.
TranslationalRelevance:Stratifyingpatients in the clinicwith a rareCFIvariantwill facil-
itate screening and targetingpatientsmost likely tobenefit fromcomplement therapies.
Introduction
Age-related macular degeneration (AMD) is a
leading cause of irreversible blindness worldwide, and
the number of people with AMD is projected to
increase from 196 million in 2020 to 288 million
in 2040.1 This slowly progressive, neurodegenerative
disease of the retina usually manifests after 60 years
of age and can markedly reduce quality of life. Loss
of central vision can occur secondary to disrup-
tion and death of photoreceptor cells in the macula
related to atrophy or neovascularization. Although
diet, smoking, and other behavioral factors are associ-
ated with the risk of advanced AMD (AAMD),2 it has
become increasingly evident that polymorphisms and
rare variants in genes encoding complement system
proteins also play a critical predisposing role.2,3
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The complement system not only defends the
host against microbes but also facilitates processing
and clearance of damaged/altered cells and tissues.
Complement is activated via three major cascades:
the classical, lectin, and alternative pathways. Each is
uniquely engaged but they share the common goal
of promoting the inflammatory response and alter-
ing the membranes of infectious microbes. Because
the complement system provides a rapidly activated
as well as a potent surveillance and effector mecha-
nism, strict control is required to avoid damage to
self-tissue. Thus, inhibition of complement activation
is mediated by both plasma and cell-bound regula-
tors. For example, the serine protease complement
factor I (FI), in conjunction with cofactor proteins
such as factor H (FH) or membrane cofactor protein
(MCP, CD46), modulates the complement cascade
through proteolytic cleavage of C3b generated by
each pathway. The prevailing hypothesis is that an
overly exuberant inflammatory response, driven by
an inadequately regulated complement cascade result-
ing primarily from genetic alterations, is a major
player in the pathophysiology of AAMD.3–7 Thus,
for a given degree of retinal injury, there is likely
an excessive degree of complement activation, which
is damaging to the retina. This undesirable response
to injury may affect the retinal pigment epithelium,
drusen formation, and/or the local vasculature leading
to a predisposition and an acceleration of the disease
process.
Genetic variants in CFI and CFH are associated
with AAMD.6,8–13 These variants range from common
polymorphisms, conferring relatively low to moderate
risk, to rare variants with nearly complete penetrance
and high risk. Also, the rare variants with high impact
which occur in families lead to younger age of onset
of AMD.9,11,13,14 The association between AMD and
a common variant in CFI was first implicated in 2009
by Fagerness et al.12 In 2013, a targeted sequencing
study of 681 genes and 2493 individuals led to the
discovery of a burden of 59 rare CFI variants associ-
ated with AMD.6 Loss of function variants had the
greatest impact on increasing risk of AMD.6 Studies
have also noted a strong predisposition to AAMD
in those with reduced serum FI levels and, in a few
cases, a reduction in catalytic activity has been impli-
cated.6,7 However, a majority of the variants in theCFI
gene are still uncharacterized. To further investigate
the pathophysiologic implications of harboring a rare
variant in CFI, we interrogated the functional activity
of this serine protease in serum samples using a serum-
based assay (ARVO 2018, Baciu et al. IOVS 2018;
59(9):790 andARVO2020, Java et al, accepted abstract,
IOVS 2020; 61(7):3651).
Methods
Patients
Individuals with and without rare heterozygousCFI
genetic variants were identified based on our previous
studies.6,7 Briefly, targeted sequencing was performed
in a cohort of 2828 individuals (1870 with and
958 without AAMD) in which 172 individuals were
found to carry a rare allele (minor allele frequency
<0.01) in CFI (Supplementary Fig. S1). A search for
variants was further extended by conducting Sanger
sequencing on samples from 838 individuals (396 with
and 442 without AAMD) from which 59 additional
individuals with CFI genetic variants were identified.
Thus the number of individuals carrying a rare CFI
variant was 231 (172 + 59) from an initial cohort of
3666 (6.3%). To explore the effects of rareCFI variants
on FI antigenic levels and functional activity, we next
identified individuals for whom serum samples were
available. There were 106 carriers of rare variants
with serum available including individuals with
(n = 78) and without (n = 28) AAMD. The compar-
ison cohort included 93 noncarriers of rare variants
in CFI matched to carrier individuals by age at date
of sample collection within two years, with AMD
(n = 49) and without AMD (n = 44). Presence
or absence and stage of maculopathy was graded
using our five-stage Clinical Age-Related Maculopa-
thy Staging system.15 Advanced AMD was defined as
either geographic atrophy or neovascular disease, based
on review of ocular records, fundus photography,
optical coherence tomography, and autofluorescence
images.
This research followed the tenets of the Declaration
of Helsinki. All individuals in this study were partic-
ipants in ongoing genetic and epidemiologic studies
of macular degeneration approved by the institutional
review board. Informed consent was obtained from
each subject.
FI Antigenic Concentration
We obtained serum samples according to our
standard protocol, which included drawing a fasting
blood sample, refrigerated centrifugation within
10 to 30 minutes and storage at −140°C. Measure-
ment of FI antigenic levels was conducted by the
National Jewish Health Advanced Diagnostic Labora-
tory (Denver, CO,USA), using radial immunodiffusion
(normal range 29.3– 58.5 μg/mL).16 C3 was quanti-
tated by standard clinical laboratory nephelometric
methodology (normal range 0.79–1.67 mg/mL).
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FI Activity Assay
A previously described cofactor assay was modified
in which FI converts substrate C3b to iC3b indepen-
dent of the C3b and FH concentration in the serum
sample (Supplementary Fig. S2).17 The effect of
endogenous FH and C3b was minimized by diluting
serum to 0.04% in PBS (phosphate-buffered saline)
solution (Supplementary Fig. S3). FI activity was then
determined after the addition of purified, exogenous
C3b and FH (final concentration 1.9 μmol/L and
290 nmol/L, respectively; Complement Technology,
Tyler, TX, USA) at 37°C for 20 minutes (Supplemen-
tary Fig. S4). At the end of the incubation period, the
reaction was halted by chilling in an ice bath followed
by a 1:500 dilution in enzyme-linked immunosorbent
assay (ELISA) buffer (Quidel, San Diego, CA, USA).
Concentration of iC3b was determined by ELISA
using MicroVue iC3b EIA (Quidel) per the manufac-
turer’s instructions. Under these conditions, up to ∼
40% of the C3b can be processed to iC3b. This assay
was also performed in the absence of exogenous C3b
and in the presence of patient serum alone. The iC3b
was not detected in either of these conditions. Each
patient sample was run twice with iC3b levels quanti-
tated in duplicate. Data points represent the average of
the two runs. Coefficient of variability of the iC3b assay
within a plate was 4.2%± 3.6% and between plates was
3.5% ± 2.6%.
The mean iC3b level was also used to quantitate
the ratio iC3b/FI; i.e., the quantity of iC3b generated
per unit (20 μg/mL) of FI. Data were collected using
ELISA reader MR5 (Molecular Dynamics, Sunny-
vale, CA, USA) and analyzed using Softmax Pro V6.3
(Molecular Probes, Invitrogen, OR, USA). Data were
graphed and statistical analyses performed using Prism
Graph v6.
Statistical Analysis
To compare the FI antigenic concentrations among
individuals with and without rare variants, box plots
were created with medians and quartiles [first quartile
(Q1) and third quartile (Q3)]. The box length ranging
from Q1 to Q3 is the interquartile range (IQR). To
show possible outliers, the whiskers were shortened
to a length of 1:5 times the box length, and points
beyond that are outliers (Q3 + 1.5*IQR). Similarly,
box plots were created for the iC3b generation and
for the iC3b generation per each unit of FI. P values
were computed to test whether FI antigenic levels
and functional activity of carriers were different from
those of noncarriers by fitting an analysis of variance
model (ANOVA) and performing Tukey’s “Honest
Significant Difference”method for multiple test correc-
tion. In addition, P values were computed to test
whether there were differences between the carriers
of rare CFI variants and non-carriers, with respect
to demographic (age, sex, race), behavioral (smoking
status and body mass index [BMI]) and AAMD status.
Fisher’s exact test was performed for categorical data
and a two-sample t-test was performed for the remain-
ing continuous data (age and BMI). These box plots
and P values were generated with R programming
language (https://www.r-project.org/).
Results
Individuals with and without rare heterozy-
gous CFI genetic variants were identified based
on our previous experiments (Supplementary
Fig. S1).6,7 Demographic data for the carriers and
non-carriers of CFI variants are shown in Supplemen-
tary Table S1. There were no significant differences
between carriers and non-carriers of rare CFI variants
regarding age, race, sex, smoking status or BMI. In our
previous analyses, measurement of serum antigenic
levels demonstrated that patients with AAMD carry-
ing a rare CFI variant had lower mean FI compared
with non-AAMD individuals (P < 0.001).6,7 However,
although the effect of CFI genetic variants resulting
in low FI levels in the pathogenesis of AAMD was
apparent, the functional impact of the rare genetic
variants which did not result in low antigenic levels
of the protein remained unclear. Therefore we used
a serum-based assay to more definitively ascertain
the enzymatic activity of such variants and corre-
lated these results with the antigenic levels. This key
role of FI, known as cofactor activity, prevents C3b
from engaging the feedback loop of the alternative
pathway. In this assay, FI in the presence of a cofactor
protein, FH cleaves the α′ chain of C3b to form iC3b
(Supplementary Fig. S2). The effect of endogenous
FH and C3b was eliminated by diluting serum to
0.04% in PBS (phosphate-buffered saline solution)
(Supplementary Fig. S3). Generation of iC3b showed
a linear correlation (r, 0.82) with FI antigenic levels
(Supplementary Fig. S4).
Measurement of FI antigenic levels and quantifi-
cation of the cofactor activity for each variant (iC3b
generation and iC3b per unit of FI) using the serum-
based assay allowed us to categorize the variants into
three types (Table). Type 1 variants were defined as
those that demonstrated low FI antigenic levels and
low iC3b generation, but the iC3b generated per unit
of FI (iC3b/FI) was normal when compared to controls
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Table. Classification of the Three Complement Factor I (CFI) Rare Variant Types Based on Antigenic Levels and
Functional Activity
Variant Type FI Antigen Level iC3b Generation iC3b Per 20 μg/mL FI
1 Low Low Normal
2 Normal Low Low
3 Normal Normal Low
FI, Factor I; iC3b, A complement cleavage product derived fromC3b by the combined action of Factor H and Factor I, known
as cofactor activity.
(non-carriers of rare variants with and without AMD).
Type 2 variants were defined as those that had normal
FI antigenic levels but exhibited low iC3b genera-
tion and low iC3b/FI. Variants defined as Type 3
demonstrated normal FI levels as well as normal iC3b
generation, but iC3b/FI was low.
Type 1 variants demonstrate reduced FI expression
(P < 4E-08, compared to no AMD and no variant)
(Fig. 1) and iC3b generation (P < 4E-08, compared to
no AMD and no variant) (Fig. 2) with both measures
falling within the lower quartile of controls. Conse-
quently, these patients are haploinsufficient due to lack
of protein being synthesized or secreted by the variant
allele. This was further confirmed by the results indicat-
ing that per unit (20 μg/mL of FI) activity was not
significantly different from controls (Fig. 3). Thus, if
functional activity is expressed as iC3b generated per
unit of FI, the measurement normalizes (P = 0.188,
compared to no AMD and no variant), in keeping with
expression of a functionally intact protein by the wild-
type allele. Eighteen variants identified in 35 patients
with AAMD belong to Type 1. Of note, one of five
patients carrying the CFI variant A240G and two of
three patients carrying the CFI variant G162D have
normal FI antigenic concentrations (Fig. 1A). A limita-
tion of this assay is that we are unable to quantitate the
relative proportion of the mutant vs wild type protein.
It has long been known that FI is an acute phase
protein and that serum levels can vary substantially.18
The potential therefore exists in an individual with a
Type 1 mutant allele for the wild type allele to be upreg-
ulated, normalizing the FI levels, and thereby masking
the effect of the Type 1 variant. We have demonstrated
by in vitro analysis that these mutations (G162D and
A240G) are not secreted (not shown), andwe can there-
fore surmise that all of the FI in both of these patients is
the wild type protein. Furthermore, these variants have
been reported previously in patients in whom the FI
levels were low.6,7,19,20
Type 2 variants show FI antigenic levels that are
not different from controls (P = 0.93, compared
with no AMD and no variant) but demonstrate
significant decreases in degradation of C3b to iC3b (P
< 0.0005, compared with no AMD and no variant)
(Figs. 1 and 2). Relative to the results in Type 1, if
expressed as iC3b generated per unit of FI, the level
is decreased when compared to controls (P < 0.0009,
compared with no AMD and no variant) (Fig. 3). This
is in keeping with a rare variant in which the protein is
secreted normally but has reduced functional activity
(consistent with a haploinsufficiency phenotype). Six
variants identified in seven individuals (six with and
one without AAMD at the time of analysis) belong to
this category.
We further classify a group of Type 3 variants that
demonstrate normal to high normal FI antigenic levels
(P < 0.0004, compared to no AMD and no variant)
and apparently normal degradation of C3b to iC3b
(P = 0.99, compared to no AMD and no variant)
(Figs. 1 and 2). However, iC3b generation per unit
of FI is low (P < 0.00007, compared to no AMD
and no variant) (Fig. 3). Fifteen variants identified in
64 individuals belong to this group. The normalization
of iC3b is likely associated with the modest increase
in FI levels. Whether the elevated FI levels reflect an
increase in the secretion of the WT allele (because of
the acute phase nature of FI) or a prolonged half-life
of the variant allele remains to be determined. Variants
belonging to Type 3 are dysfunctional based on the
low iC3b per unit of FI, but likely of lower penetrance
compared to those belonging to Types 1 and 2. Of
note, the most frequent variant in this group, K441R,
identified in 16 individuals, demonstrates wide variabil-
ity in the FI antigenic levels. This is possibly due to the
ratio of WT and variant allele expression as explained
above. To more definitively delineate the functional
activity of this variant, we plan to produce this variant
recombinantly. Another variant, R202I, is categorized
as Type 3 but when present as a double mutant
with A356P/R202I, it demonstrates a Type 2 defect.
We believe this may likely be due to the combined
deleterious effect of both variants. This result and its
interpretation will also need to be validated using
recombinant proteins.
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Figure 1. FI antigenic levels. (A) Individual values are shown as solid blue circles for patients with AAMD and purple circles for individuals
without AAMD. Normal range (29.3–58.5 μg/mL) is represented by the black horizontal lines. The rare genetic variants are listed on the X-axis.
The numbering system includes the signal peptide of 18 amino acids. (B) Box plots demonstrate that Type 1 variants have low FI antigenic
levels (P< 4E-08, compared with no AMD and no variant; P< 4E-08, compared to AMD and no variant) whereas type 2 (P= 0.93, compared
withnoAMDandnovariant;P=0.70, comparedwithAMDandnovariant) and type3variants havenormal tohighantigenic levels compared
with controls (P< 0.0004, compared with no AMD and no variant; P< 0.009 compared to AMD and no variant). Controls (noncarriers of rare
variants, with and without AMD), demonstrate normal antigenic levels of FI.
As shown in Figures 1 to 3, noncarriers of
rare CFI variants, with and without AAMD,
have normal (one exception with a high value) FI
antigenic levels (29.3–58.5 μg/mL), iC3b generation
(108 ± 19.9 μg/mL), and iC3b/unit FI (56.6 ± 7.3).
Also, there was no significant difference in FI antigenic
levels (P = 0.92) or function (P = 0.17) in noncarriers
regardless of disease status (with or without AAMD).
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Figure 2. The iC3b generation. FI functional activity is ascertained by the quantity of iC3b generated as determined by ELISA. (A) Individual
values are shown as solid green circles for AAMD and purple circles for those without AAMD. Black horizontal line represents mean iC3b value
for controls. (B) Box plots demonstrate that both type 1 (P< 4E-08, compared with no AMD and no variant; P< 4E-08, compared with AMD
and no variant) and type 2 variants (P< 0.0005, comparedwith no AMD and no variant; P< 4E-08, comparedwith AMD and no variant) have
decreased iC3b generation compared to controls. Type 3 variants portray normal iC3b generation (P= 0.99, compared with no AMD and no
variant; with P= 0.04, compared with AMD and no variant). Noncarriers (with and without AMD) also demonstrate normal iC3b generation.
Discussion
Rare genetic variants in CFI have been associated
with AAMD.6,7 However, a majority of the variants
have not been functionally characterized and many
are classified based on in-silico analyses as benign,
likely benign, or variants of uncertain significance. This
inability to ascertain the function of genetic variants
impairs our understanding of the disease pathogene-
sis and is an impediment to personalized management
of AAMD. In this study, we have implemented a high
throughput serum-based functional assay, similar to
that described by Lashkari et al.,17 to more definitively
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Figure 3. The iC3b generation per antigenic unit (20 μg/mL) of FI. (A) Individual values are represented by solid red circles for patients with
AAMD and purple circles for those without AAMD. Black horizontal line represents mean iC3b/FI for controls (noncarriers of rare variants with
and without AMD). (B) Box plots demonstrate that Type 1 variants have a normal iC3b per unit of FI (P = 0.188, compared to no AMD and
no variant; P= 1.00, compared with AMD and no variant). This is consistent with variants that result in expression by one allele (haploinsuf-
ficiency) of a functionally normal protein. Type 2 (P < 0.0009, compared to no AMD and no variant; P < 4E-08, compared to AMD and no
variant) and type 3 variants (P < 0.00007, compared to no AMD and no variant; P < 4E-08, compared to AMD and no variant) demonstrate
decreased iC3b per unit of FI since these variants result in a protein that is secreted normally but has decreased function. Noncarriers have
normal iC3b generation/FI.
determine the significance of FI variants. As outlined
below, our results produced several key findings.
First, a largemajority (78 of 106) of individuals who
are haploinsufficient for FI develop AAMD. Haploin-
sufficiency presents as either a quantitative defect (low
antigenic and thus reduced functional activity of FI)
with Type 1 variants or normal antigenic levels but
low functional activity (Types 2 and 3). A variant
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belonging to Type 3 produces a protein that is less
dysfunctional than those generated by genetic variants
in Type 2, but it is not equivalent in regulatory activ-
ity to wild-type. Therefore it would also be expected
that a moderate deficiency state would have a lower
penetrance. The main point is that Type 3 variants have
a functional deficiency, i.e., being less defective than
Type 2 variants but not equivalent to wild-type. Impor-
tantly, FI-mediated complement regulatory activity is
normal in most individuals without a rare variant (with
or without AMD).
Second, remarkably, 42% of the rare genetic
variants in this AAMD cohort have been observed
in patients with atypical hemolytic uremic syndrome
(aHUS),21–25 a thrombotic microangiopathy in which
rare mutations in CFI are causative in 5% to 15%
of patients. This association of variants causing two
apparently disparate diseases is striking. Atypical
hemolytic uremic syndrome features acute endothelial
injury that often arises in about 50%of the time in early
childhood, whereas AMD features biological debris
above and below the retinal pigment epithelium and is a
disease manifested primarily in older adults. An emerg-
ing theme over the past decade, particularly based on
insights gained from genetic studies, is that modulation
of complement inhibitory activity predisposes to acute
thrombomicroangiopathies such as aHUS, as well as to
dysfunctional debris handling causing a chronic disease
such as AMD. Gaining insights into the functional
capabilities of these variants may help to delineate
patients who are at risk of developing an acute kidney
disease early in life versus those who are at risk of
manifesting another chronic debilitating condition at
an older age. Type 1 variants P50A, P64L, G119R,
V152M, G162D, N177I, A240G, A258T, G287R and
R474X,17,19–22 Type 2 variant E554V,26,27 and Type 3
variants G261D, R317W, R406H, K441R and P553S
have all been reported in aHUS.20,21,28–30 Further
analyses of those variants that overlap versus those that
are distinctly observed in one or the other disease could
be informative.
Third, as anticipated, the functional characteriza-
tion of CFI variants facilitated more accurate inter-
pretations compared to the in-silico predictions. As
an example, E109A, N177I, R317W, R406H, K441R
and G500R are predicted to be “benign” or “likely
benign” by in-silico models, but based on our current
data, as well as prior structure-function analyses of
these variants using recombinant proteins,24,25 they are
deleterious.
As noted, a further and in some cases a critical
approach, to facilitate understanding of FI variants
is to produce the variants recombinantly, and then to
analyze their function, including (a) utilizing multi-
ple cofactor proteins (C4 binding protein, membrane
cofactor protein, complement receptor 1 as well as
Factor H), (b) carrying out assessments on the cell
membrane as well as in the fluid phase, and (c)monitor-
ing cleavage of both the alternative and classical/lectin
pathway fragments (C3b andC4b, respectively).We are
now taking this overall approach for variants belonging
to Type 3 to rigorously assess their functional reper-
toire as well as for other outliers and putative discrep-
ancies.28,30
Measuring serum antigenic levels and functional
activity of FI provides a quick, simple, practical and
low-cost screening tool in the clinical laboratory. We
recommend that patients with and without AAMD
who have a rare variant in CFI should undergo an
assessment of serumFI antigenic levels. If the antigenic
level is low, as illustrated here and in the literature,7 the
patient is appropriately classified as carrying a defec-
tive Factor I. If the antigenic level is normal, then a
functional assessment for FI, such as the serum-based
assay reported here, should be performed. If the assay
shows low function, the patient has reduced cofactor
activity and is therefore predisposed to AAMD.
Overall, these results provide compelling functional
evidence for a key role of impaired FI-mediated regula-
tory activity of the complement system’s alternative
pathway in the pathogenesis of AAMD. Results also
have direct clinical relevance. Identification of individ-
uals with AAMD in the clinic who have a rare CFI
variant, and stratifying them according to this assay
into Type 1, 2 or 3CFImutations, will facilitate screen-
ing and targeting patients most likely to benefit from
complement pathway related therapies. Such an assay
therefore facilitates a personalized treatment strategy
for AAMD as currently underway in some clinical
trials. Results may also be relevant for complement-
mediated renal diseases.
In conclusion, AMD is a chronic disease in which
the therapeutic goals are to slow the rate of progres-
sion or, preferably, halt the retinal damage. In AAMD,
approximately 10% of patients carry a rare genetic
variant in FH or FI, the two plasma regulators that
inhibit complement activation at the key C3 step. In
a clinical trial using a complement-based therapeu-
tic, the investigators would preferentially study such
patients. To ascertain them, we would recommend
a workup consisting of a genetic screen for a rare
variant. If identified, then an antigenic level would
be obtained. In approximately 30% of cases for FH
and 50% for FI, a patient carrying a rare variant
will be haploinsufficient with a low antigenic level. If
level is in the normal range, a functional assay (such
as on FI as performed in this study) would next be
obtained. This personalized medicine approach is
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being used for clinical trials (https://www.clinicaltri
alsregister.eu/ctr-search/trial/2017-003712-39/GB;
https://clinicaltrials.gov/ct2/show/NCT04246866?term
= Gemini&cond = AMD&draw = 2&rank = 1)
and, assuming an effective anti-complement thera-
peutic agent is identified, will be required to target
AMD patients who are most likely to benefit from
a complement therapeutic agent. This approach is
already being accomplished in aHUS29 and should be
undertaken in AAMD, and other diseases in which
a patient carries a rare variant. In view of the drug
costs and duration of therapy likely to be necessary
to treat AAMD, these analyses will eventually be
required.
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